- European Commission approves Amgen's IMDYLLTRA (tarlatamab) for adults with extensive-stage small cell lung cancer as a second-line treatment.
- Decision follows positive Phase 3 results showing a survival benefit over standard chemotherapy.
- Approval adds a new marketed therapy to Amgen's oncology portfolio in a high unmet medical need area.
For investors following Amgen (NasdaqGS:AMGN), the European Commission's green light for IMDYLLTRA arrives with the stock trading around $328.26. Shares are up 16.8% over the past year and 62.7% over three years, during a period when the company has been active in building out its drug portfolio, including in oncology.
This new approval gives Amgen an additional foothold in European oncology markets and broadens its exposure to lung cancer treatment. Investors may watch how quickly IMDYLLTRA is adopted, how pricing and reimbursement develop across member states, and how this therapy fits alongside other assets in Amgen's cancer pipeline.
Stay updated on the most important news stories for Amgen by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Amgen.
📰 Beyond the headline: 1 risk and 3 things going right for Amgen that every investor should see.
The EC approval of IMDYLLTRA gives Amgen a differentiated asset in a tough part of lung cancer where treatment options are limited and relapse after first-line platinum-based chemotherapy is common. The DeLLphi-304 data, showing a 40% reduction in risk of death and a median overall survival of 13.6 months versus 8.3 months on chemotherapy, may support uptake if clinicians view the benefit as clinically meaningful relative to existing second-line options from competitors such as Roche, AstraZeneca and Merck. That said, the safety profile, especially cytokine release syndrome and the need for 6 to 8 hours of monitoring after early doses, could influence how quickly hospitals adopt the drug and how widely community centers use it.
How This Fits Into The Amgen Narrative
- IMDYLLTRA directly aligns with the focus on targeted therapies, as it uses DLL3 to direct T cells against small cell lung cancer cells. This fits with the narrative around late-stage oncology assets supporting growth.
- The need for intensive monitoring for cytokine release syndrome in early cycles may limit initial real-world use. This could temper the contribution some investors expect from new high-margin therapies.
- The breadth of the DeLLphi program, including earlier-line and combination studies, may not be fully captured in high-level narrative summaries that focus on broader product groups rather than specific small cell lung cancer opportunities.
Knowing what a company is worth starts with understanding its story. Check out one of the top narratives in the Simply Wall St Community for Amgen to help decide what it's worth to you.
The Risks and Rewards Investors Should Consider
- ⚠️ High rates of cytokine release syndrome and other adverse reactions, along with monitoring requirements, could constrain how broadly IMDYLLTRA is used across treatment centers.
- ⚠️ Analysts have flagged that Amgen’s debt is not well covered by operating cash flow, so additional investment to support the IMDYLLTRA program and wider oncology expansion adds another draw on resources.
- 🎁 IMDYLLTRA gives Amgen a first in class immunotherapy targeting DLL3, reinforcing its presence in oncology at a time when peers such as Roche and AstraZeneca are also active in lung cancer.
- 🎁 The wider DeLLphi clinical program, which includes multiple studies in earlier lines and combinations, provides several potential paths to extend the IMDYLLTRA franchise if future data support broader use.
What To Watch Going Forward
From here, investors can watch how quickly IMDYLLTRA is added to treatment guidelines, reimbursement decisions across major EU markets, and any early real-world data on safety and duration of therapy. Uptake trends relative to existing second-line chemotherapies and immunotherapies from companies such as Merck and Roche will help indicate the scale of the commercial opportunity. Progress in other DeLLphi trials, including first-line and maintenance settings, will also be important for understanding whether IMDYLLTRA remains a niche second-line product or becomes a larger pillar within Amgen’s oncology portfolio.
To stay informed about how the latest news impacts the investment narrative for Amgen, visit the community page for Amgen to keep up with the top community narratives.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com